Ananda Doses First Patient in CBD Trial for Chemo Nerve Pain

Ananda Pharma has dosed the first patient in a mid-stage trial testing whether a cannabidiol drug can ease one of chemotherapy’s most persistent side effects: the nerve damage that leaves cancer patients with burning, numbness, and pain in their hands and feet. The UK biopharmaceutical company Ananda Pharma said on July 17, 2026 that a participant had been enrolled, randomised, and given the first dose of either its CBD-based oral solution, MRX1, or a matching placebo.

The study, called ACTiON, is a double-blind, placebo-controlled crossover trial aiming to enrol 92 participants with chemotherapy-induced peripheral neuropathy, or CIPN. It is led by Professor Marie Fallon at the University of Edinburgh and funded by the National Institute for Health and Care Research (NIHR) through an Efficacy and Mechanism Evaluation grant. That funding route matters: the money comes from a public research body after independent scientific review, not from the company’s own balance sheet, and it signals that the research question cleared external peer scrutiny. Beyond pain relief, the trial will track MRX1’s effect on quality of life and how heavily patients lean on health services.

The scale of an unmet need

CIPN is both common and hard to shake. A widely cited systematic review and meta-analysis — co-authored by Fallon herself — found that about 68% of patients had neuropathy in the first month after chemotherapy, with roughly 30% still affected six months or more later. Because the numbness and pain can become dose-limiting, oncologists sometimes cut chemotherapy short, a trade-off that can work against the cancer treatment itself. Ananda puts the UK burden at more than 140,000 new cases a year, with US figures near 400,000 and annual costs around $2.5 billion.

The company describes CIPN as having “no effective therapies,” and clinical guidance is close to that. The American Society of Clinical Oncology’s 2020 practice guideline recommends no drug at all for preventing CIPN and endorses just one — the antidepressant duloxetine — for treating established painful neuropathy, while noting that even its benefit is limited. That thin toolkit is the gap a new drug would have to fill.

What the evidence on CBD actually shows

On paper, CBD is a reasonable candidate. In rodent models of CIPN, it reduces neuropathic pain behavior, and it acts on pain-signaling targets that sit outside the classic cannabinoid receptors. But the human evidence remains thin and mixed, a pattern that shows up across cannabinoid research in neuropathic pain. A 2025 randomised controlled trial of a CBD-and-THC combination makes the point plainly: it set out to randomise 100 patients but reached only 46, and its main analysis found no difference between the cannabinoid and placebo, with just a secondary signal on sensory symptoms. Underpowered studies like that are precisely why a fully enrolled, placebo-controlled trial is worth running — earlier work on oral CBD in chemotherapy neuropathy has faced the same limits.

MRX1 is an effectively THC-free CBD oral solution, which lets it be dosed at levels that would be impractical with a psychoactive product. Earlier in 2026, Ananda reported clean Phase 1 safety and tolerability data in healthy volunteers — a meaningful checkpoint, because high-dose CBD, as used in the approved childhood-epilepsy medicine Epidyolex, can raise liver enzymes. The crossover design, in which each participant receives both MRX1 and placebo in sequence, squeezes more statistical power out of a modest sample. It also puts weight on managing CIPN’s notoriously high placebo response, which has muddied earlier trials.

What to watch

The milestone here is enrollment, not efficacy. Ananda’s chief executive, Melissa Sturgess, called it “gold standard work,” but dosing a single patient marks the start of data collection, not a result. As a Phase 2 study, ACTiON is built to detect an efficacy signal and refine dosing; confirming that MRX1 works would take larger trials, and any regulatory decision is years away.

ACTiON now runs in parallel with ENDOCAN, a second Phase 2 study testing MRX1 against endometriosis-associated pain and funded by NHS Scotland. The two trials give Ananda read-outs in distinct pain conditions on broadly similar timelines, after the company narrowed its pipeline to MRX1 and stepped back from an earlier epilepsy programme.

For now, the substance is modest and specific: a public research body judged the question worth funding, a properly powered trial has begun, and a CBD formulation with a clean early-safety record is being measured against placebo in a condition where the current standard of care helps only a little. The evidence that will decide whether MRX1 belongs in that gap has yet to be collected.